Closed Loop Medication Management: From Vision to Reality

Why transforming medication management requires more than technology

Closed Loop Medication Management (CLMM) has become an important ambition for hospitals seeking to improve medication safety, operational efficiency and the working environment of healthcare professionals. The vision is compelling: a digitally connected medication process in which prescribing, verification, preparation, dispensing, distribution and administration form one coherent system. Yet translating this vision into everyday hospital practice remains a considerable challenge.

Over more than three decades of working in hospital pharmacy, I have seen how technological possibilities have evolved. Automated storage systems, Unit Dose solutions, automated dispensing cabinets, electronic prescribing and bedside scanning have created opportunities that were difficult to imagine only a generation ago. At the same time, experience has taught me that implementing Closed Loop Medication Management is not primarily a technology project. It is a transformation of the entire medication management process.

A closed loop is more than a collection of technologies

Hospitals often approach medication management transformation through individual investments. A new pharmacy robot, a Unit Dose system, automated dispensing cabinets or an electronic medication administration record may each offer significant benefits. However, introducing these technologies does not automatically create a closed loop. The real value emerges when the individual components work together within a coherent medication process, allowing medication information to remain consistent and traceable as it moves between prescribing systems, pharmacy applications, automation equipment and the point of administration.

Achieving this requires more than technical interfaces. It also demands agreement on processes, responsibilities, information flows and the way healthcare professionals interact with the system. A technically connected solution can still leave important gaps in the medication process, particularly when organisational arrangements and clinical workflows have not been considered sufficiently.

Start with the medication process, not the equipment

One of the most important decisions in a CLMM programme comes before selecting technology. How should medication move through the hospital? Which activities should take place centrally in the pharmacy, and which should remain close to the patient? Where does automation add value, and where is professional judgement essential? These questions need to be answered in the context of the individual hospital, rather than through a predetermined technological solution.

Hospital size, clinical specialisation, existing infrastructure, staffing, medication profiles and organisational ambitions all influence the most appropriate approach. A highly centralised model may be suitable for certain medication flows, while decentralised solutions may offer advantages for others. In many hospitals, a hybrid approach deserves serious consideration. The objective should therefore not be to maximise automation or centralisation, but to design a medication process that supports patient safety, reliable operations and effective use of healthcare professionals’ time. Technology should follow the process strategy, rather than determine it.

Interoperability is a prerequisite, not an afterthought

A closed medication loop depends on information moving reliably between systems. Electronic prescribing, pharmacy information systems, medication logistics software, automated dispensing technology and bedside administration systems must exchange information accurately and at the right moment. Although this may sound straightforward, interoperability is frequently one of the most demanding aspects of implementation.

Different systems may use different data structures, identifiers, workflows and interpretations of medication information. Even when interfaces are technically available, the information exchanged may not fully support the intended clinical process. Interoperability must therefore be addressed from the beginning of a CLMM programme, with a clear understanding of both the technical requirements and the underlying medication workflows. It is not simply an IT workstream, but a shared responsibility involving hospital pharmacy, clinical departments, IT specialists and technology suppliers.

The business case must look beyond labour savings

Investment in medication management automation is frequently justified through expected efficiency improvements. Reducing manual handling, improving inventory management and making better use of staff time are legitimate objectives, but a business case based solely on labour savings provides an incomplete picture. A comprehensive assessment should also consider medication safety, traceability, process reliability, medication waste, working conditions and the organisation’s capacity to respond to future demands.

An additional complication is that benefits do not always appear in the department making the investment. An investment in the hospital pharmacy may reduce workload on nursing wards, while better medication information may support clinical decision-making and improved traceability may strengthen quality management across the hospital. Consequently, the costs of transformation and its benefits are not necessarily located within the same organisational budget. A credible business case needs to make these relationships visible, distinguish measurable benefits from expected improvements and identify the assumptions on which investment decisions depend.

Implementation begins long before go-live — and continues afterwards

A successful technical installation is an important milestone, but it is not the same as a successful implementation. Medication management systems become valuable only when they function reliably within everyday clinical and pharmaceutical workflows. This requires careful preparation, realistic testing, clear responsibilities, staff training and sufficient attention to exceptions. Urgent medication requests, prescription changes, unavailable medicines, returned doses and temporary system interruptions are all situations that need to be considered during process design, rather than being treated as peripheral issues.

Equally important is the period following go-live. Processes need to stabilise, technical and organisational issues must be resolved, and performance should be assessed against the original objectives. Experience shows that the transition from project implementation to sustainable operations deserves as much management attention as the technology itself. Without this attention, even technically sophisticated solutions may struggle to deliver their intended value.

Healthcare professionals must be part of the transformation

CLMM changes the way hospital pharmacists, pharmacy technicians, nurses and physicians work together. Tasks may move between departments, existing routines are replaced and new responsibilities emerge. These changes can create opportunities to reduce repetitive work and allow healthcare professionals to concentrate on activities where their expertise adds greater value. However, they can also introduce new workload when processes are poorly designed or responsibilities are not sufficiently clear.

For this reason, change management cannot be treated as a final training activity shortly before go-live. Healthcare professionals need to be involved in designing, testing and improving the future medication process. Their practical experience is essential for identifying risks, understanding exceptions and creating workable solutions. Ultimately, the success of CLMM depends not only on the capabilities of the technology, but also on the confidence and consistency with which people use the new processes.

From Closed Loop Medication Management ambition to a realistic roadmap

A hospital does not need to transform its entire medication process in a single step. A structured approach can begin with understanding the current situation, identifying risks and opportunities, and defining a shared vision for the future. From there, alternative scenarios can be developed and evaluated against clinical, operational, technical and financial criteria. This creates the foundation for a realistic roadmap that connects strategic objectives with investment decisions, technology selection, organisational preparation and implementation.

Such a roadmap should also recognise dependencies between different components of the medication process. Certain improvements may require changes to information systems, organisational responsibilities or workflows before automation can deliver its intended benefits. A phased approach can help reduce complexity, support organisational learning and make progress measurable, provided that the individual steps remain connected to the overall vision.

The real objective: a safer and more sustainable medication process

Closed Loop Medication Management is not an end in itself. Its purpose is to help hospitals deliver medication safely, efficiently and reliably, while supporting the professionals responsible for patient care. Achieving this requires a combination of strategic vision, process design, digital integration, appropriate technology, economic justification and organisational change. There is no single technology or standard implementation model that can deliver all of this.

The challenge is to bring these elements together in a solution that fits the hospital and continues to perform beyond the initial implementation. Ultimately, the future of medication management will not be defined by how much technology hospitals install, but by how effectively they connect technology, processes and people around the needs of patients.

---

Patrick van Oirschot is an independent consultant and owner of GPP Support BV, specialising in Closed Loop Medication Management, hospital pharmacy strategy, automation and digital transformation. He is also a co-founder of the Asclepius Project, a European network of medication management experts.